Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
September 24 2020 - 4:12PM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a
biopharmaceutical company with a pipeline of clinical-stage assets
designed to modulate immunological pathways that are implicated
across a spectrum of diseases, today announced that the company’s
virtual Rilonacept Analyst Day will now take place on Tuesday,
September 29th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight
Time.
The event will feature presentations from the Kiniksa management
team on the market opportunity for rilonacept in recurrent
pericarditis as well as the company’s continued commercial
preparations and launch strategy. Additionally, guest speaker Paul
Cremer, MD, Cardiovascular Medicine, Cleveland Clinic, will review
the burden of recurrent pericarditis, the current treatment
landscape, and the unmet need.
Webcast and Conference
Call InformationKiniksa will host a
webcast and conference call at 8:00 a.m. Eastern Daylight Time on
Tuesday, September 29th, 2020. The presentation will be accessible
through this link as well as through the Investors & Media
section of the company's website. Individuals can also participate
by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053
(international) using conference ID number 3890078. The archived
webcast will be available on Kiniksa’s website for 14 days
beginning approximately one hour after the conclusion of the
event.
About Recurrent PericarditisRecurrent
pericarditis is a painful and debilitating autoinflammatory
cardiovascular disease that typically presents with chest pain and
is often associated with changes in electrical conduction and
sometimes buildup of fluid around the heart, called pericardial
effusion. Patients with pericarditis are deemed recurrent if they
have an additional episode after a symptom-free period of 4-6
weeks, and chronic if symptoms from any one episode last longer
than three months. Recurrent pericarditis symptoms impair qualify
of life, limit physical activities, and lead to frequent emergency
department visits and hospitalizations. There are currently no U.S.
Food and Drug Administration (FDA)-approved treatments for
recurrent pericarditis.
About RilonaceptRilonacept is a weekly,
subcutaneously-injected, recombinant fusion protein that blocks
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β).
Rilonacept was discovered and developed by Regeneron and is
approved by the FDA under the brand name ARCALYST® for the
treatment of Cryopyrin-Associated Periodic Syndromes (CAPS),
specifically Familial Cold Autoinflammatory Syndrome and
Muckle-Wells Syndrome. Rilonacept for the treatment of deficiency
of the interleukin1 receptor antagonist (DIRA) is currently pending
FDA approval following the submission of a supplemental Biologic
License Application (sBLA) in June 2020. Rilonacept in
recurrent pericarditis is an investigational drug. The FDA granted
Breakthrough Therapy designation to rilonacept for recurrent
pericarditis in 2019 and Orphan Drug designation to rilonacept for
pericarditis in 2020.
Important information about ARCALYST® (rilonacept)
Injection IL-1 blockade may interfere with immune response
to infections. Serious, life-threatening infections have been
reported in patients taking ARCALYST. ARCALYST should be
discontinued if a patient develops a serious infection. Taking
ARCALYST with TNF inhibitors is not recommended because this may
increase the risk of serious infections.Patients should not receive
a live vaccine while taking ARCALYST. It is recommended that prior
to initiation of therapy with ARCALYST patients receive all
recommended vaccinations, as appropriate, including pneumococcal
vaccine and inactivated influenza vaccine. In the initial
development program for ARCALYST, six serious adverse reactions
were reported by four patients: Mycobacterium intracellular
infection, gastrointestinal bleeding and colitis, sinusitis and
bronchitis and Streptococcus pneumoniae meningitis. The most
commonly reported adverse reactions associated with ARCALYST were
injection site reaction and upper respiratory tract infection.
Patients should be monitored for changes in their lipid profiles
and provided with medical treatment if warranted. Treatment with
immunosuppressants, including ARCALYST, may result in an increase
in risk of malignancies. Hypersensitivity reactions associated with
ARCALYST administration in clinical studies have been rare. If a
hypersensitivity reaction occurs, administration of ARCALYST should
be discontinued and appropriate therapy initiated.
About KiniksaKiniksa is a biopharmaceutical
company focused on discovering, acquiring, developing and
commercializing therapeutic medicines for patients suffering from
debilitating diseases with significant unmet medical need.
Kiniksa’s clinical-stage product candidates, rilonacept,
mavrilimumab, vixarelimab and KPL-404, are based on strong biologic
rationale or validated mechanisms, target underserved conditions
and offer the potential for differentiation. These pipeline assets
are designed to modulate immunological pathways that are implicated
across a spectrum of diseases. For more information, please
visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second Counts!
Kiniksa Investor and Media ContactMark
Ragosa(781) 430-8289mragosa@kiniksa.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Apr 2023 to Apr 2024